| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
54,480,000 as of 6/30 |
| Market
Cap: |
76.27(M) |
| Last
Volume: |
52,147 |
Avg
Vol: |
28,642 |
| 52
Week Range: |
$1.15 - $5.62 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
Company Profile Telik is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. TELINTRA, Co.'s key drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). Co. is developing TELINTRA for the treatment of blood disorders associated with low blood cell levels, such as neutropenia. TELCYTA, Co.'s second product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells. TELCYTA binds to GST P1-1, an enzyme that is elevated in many human cancers, such as ovarian, non-small cell lung, colorectal, and breast.
|
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
151,108 |
151,108 |
151,108 |
| Total Sell Value |
$0 |
$300,516 |
$300,516 |
$300,516 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2013-02-17 |
2012-11-16 |
2012-05-18 |
2011-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barry Richard |
10% Owner |
– – • |
2012-12-17 |
4 |
S |
$1.86 |
$90,049 |
D/D |
(48,390) |
243,800 |
|
25% |
|
| Barry Richard |
10% Owner |
– – • |
2012-12-13 |
4 |
S |
$2.31 |
$94,664 |
D/D |
(40,920) |
292,200 |
|
38% |
|
| Barry Richard |
10% Owner |
– – • |
2012-12-12 |
4 |
S |
$1.87 |
$115,803 |
D/D |
(61,798) |
292,200 |
|
26% |
|
| Wee Wendy |
Principal Financial Officer & |
• – – |
2010-12-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,273 |
|
5% |
|
| Barry Richard J. |
10% Owner |
– – • |
2010-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,186,055 |
11,847,125 |
|
- |
|
| Cantrall Edward W |
Director |
– • – |
2010-08-23 |
4 |
B |
$0.72 |
$4,320 |
D/D |
6,000 |
50,000 |
2.31 |
12% |
|
| Barry Richard J. |
10% Owner |
– – • |
2010-06-24 |
4 |
B |
$0.75 |
$6,684 |
D/D |
8,912 |
12,193,779 |
2.37 |
7% |
|
| Barry Richard J. |
10% Owner |
– – • |
2010-06-23 |
4 |
B |
$0.75 |
$7,837 |
D/D |
10,449 |
12,184,867 |
2.37 |
7% |
|
| Barry Richard J. |
10% Owner |
– – • |
2010-06-22 |
4 |
B |
$0.75 |
$20,312 |
D/D |
27,083 |
12,174,418 |
2.37 |
5% |
|
| Barry Richard J. |
10% Owner |
– – • |
2010-06-21 |
4 |
B |
$0.75 |
$67,663 |
D/D |
90,217 |
12,147,335 |
2.45 |
8% |
|
| Barry Richard J. |
10% Owner |
– – • |
2010-06-18 |
4 |
B |
$0.76 |
$40,508 |
D/D |
53,300 |
12,057,118 |
2.37 |
14% |
|
| Barry Richard J. |
10% Owner |
– – • |
2010-06-17 |
4 |
B |
$0.73 |
$3,212 |
D/D |
4,400 |
12,003,818 |
2.37 |
3% |
|
| Wick Michael M |
President, CEO and Chairman |
• • – |
2010-06-15 |
4 |
B |
$0.75 |
$22,636 |
D/D |
30,000 |
162,391 |
2.81 |
-8% |
|
| Barry Richard J. |
10% Owner |
– – • |
2010-06-15 |
4 |
A |
$0.76 |
$76,000 |
D/D |
100,000 |
11,999,418 |
|
- |
|
| Barry Richard J. |
10% Owner |
– – • |
2010-06-15 |
4/A |
B |
$0.76 |
$76,000 |
D/D |
100,000 |
11,999,418 |
2.45 |
- |
|
| Barry Richard J. |
10% Owner |
– – • |
2010-06-11 |
4/A |
B |
$0.72 |
$360,000 |
D/D |
500,000 |
11,899,418 |
2.45 |
- |
|
| Barry Richard J. |
10% Owner |
– – • |
2010-06-11 |
4 |
A |
$0.72 |
$360,000 |
D/D |
500,000 |
11,899,418 |
|
- |
|
| Cantrall Edward W |
Director |
– • – |
2010-06-10 |
4 |
B |
$0.70 |
$7,230 |
D/D |
10,000 |
44,000 |
2.39 |
-0% |
|
| Barry Richard J. |
10% Owner |
– – • |
2010-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
0 |
11,399,418 |
|
- |
|
| Eastbourne Capital Management Llc/ca |
10% Owner |
– – • |
2010-05-10 |
4 |
D |
$0.00 |
$0 |
I/I |
(10,317,291) |
1,532,709 |
|
- |
|
| Eastbourne Capital Management Llc/ca |
10% Owner |
– – • |
2009-09-30 |
4 |
S |
$0.79 |
$37,572 |
D/D |
(47,385) |
11,850,000 |
|
- |
|
| Black Bear Offshore Master Fund Lp |
10% Owner |
– – • |
2009-09-30 |
4 |
S |
$0.79 |
$37,572 |
D/D |
(47,385) |
7,971,542 |
|
- |
|
| Black Bear Offshore Master Fund Lp |
10% Owner |
– – • |
2009-09-29 |
4 |
S |
$0.81 |
$116,379 |
D/D |
(143,068) |
8,018,927 |
|
- |
|
| Eastbourne Capital Management Llc/ca |
10% Owner |
– – • |
2009-09-29 |
4 |
S |
$0.81 |
$116,379 |
D/D |
(143,068) |
11,897,385 |
|
- |
|
| Eastbourne Capital Management Llc/ca |
10% Owner |
– – • |
2009-09-28 |
4 |
S |
$0.84 |
$179,389 |
D/D |
(213,547) |
12,040,453 |
|
- |
|
203 Records found
|
|
Page 1 of 9 |
|
|
0.04 (2.94%) 
